Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Triple Negative Breast Cancer Malignancies”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT01150513
What this trial is testing

Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer

Who this might be right for
Breast Cancer
Chinese Academy of Medical Sciences 320
Testing effectiveness (Phase 2)WithdrawnNCT03644589
What this trial is testing

Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer

Who this might be right for
Estrogen Receptor NegativeHER2/Neu NegativeMetastatic Breast Cancer+3 more
University of Washington
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07681297
What this trial is testing

Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and Central Nervous System Disease

Who this might be right for
Advanced Solid Tumor CancerTriple-Negative Breast Cancer (TNBC)CNS Disease+1 more
National University Hospital, Singapore 154
Testing effectiveness (Phase 2)Study completedNCT00463788
What this trial is testing

Cetuximab and Cisplatin in the Treatment of "Triple Negative" (Estrogen Receptor [ER] Negative, Progesterone Receptor [PgR] Negative, and Human Epidermal Growth Factor Receptor 2 [HER2] Negative) Metastatic Breast Cancer

Who this might be right for
Breast Neoplasm
Merck KGaA, Darmstadt, Germany 181
Testing effectiveness (Phase 2)Study completedNCT02876302
What this trial is testing

Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

Who this might be right for
Inflammatory Breast Cancer (IBC)
Dana-Farber Cancer Institute 23
Early research (Phase 1)WithdrawnNCT04762901
What this trial is testing

LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer

Who this might be right for
Breast Cancer
Wake Forest University Health Sciences
Large-scale testing (Phase 3)Study completedNCT03337724
What this trial is testing

Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 579
Testing effectiveness (Phase 2)UnknownNCT04722718
What this trial is testing

Efficacy and Safety of Sintilimab and Apatinib Combined Chemotherapy in Breast Cancer

Who this might be right for
Breast Cancer
Jiuda Zhao 34
Not applicableLooking for participantsNCT02732860
What this trial is testing

Personalized Patient Derived Xenograft (pPDX) Modeling to Test Drug Response in Matching Host

Who this might be right for
Colorectal NeoplasmsColorectal CancerBreast Cancer+3 more
University Health Network, Toronto 120
Testing effectiveness (Phase 2)WithdrawnNCT02161679
What this trial is testing

Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast Cancer

Who this might be right for
Triple-negative Breast Cancer
Gilead Sciences
Testing effectiveness (Phase 2)Study completedNCT02301988
What this trial is testing

Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer

Who this might be right for
Breast Cancer
Genentech, Inc. 151
Early research (Phase 1)Study completedNCT03256344
What this trial is testing

Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases

Who this might be right for
Metastatic Triple Negative Breast CancerMetastatic Colorectal Cancer
Amgen 36
Testing effectiveness (Phase 2)Looking for participantsNCT06840821
What this trial is testing

Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin Receptors

Who this might be right for
Advanced Solid Tumors
Mainline Biosciences (Shanghai) Co., Ltd 156
Large-scale testing (Phase 3)Study completedNCT02574455
What this trial is testing

Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)

Who this might be right for
Breast Cancer
Gilead Sciences 529
Early research (Phase 1)Study completedNCT03667716
What this trial is testing

COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.

Who this might be right for
Advanced CancerOvarian CancerBreast Cancer+7 more
Compugen Ltd 121
Testing effectiveness (Phase 2)Study completedNCT03193853
What this trial is testing

TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
Joyce O'Shaughnessy 12
Testing effectiveness (Phase 2)Ended earlyNCT02124902
What this trial is testing

Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity

Who this might be right for
Triple Negative Breast Neoplasms
Washington University School of Medicine 148
Testing effectiveness (Phase 2)Active Not RecruitingNCT06399757
What this trial is testing

Investigate APL-5125 in Adults With Advanced Solid Tumors

Who this might be right for
Colorectal CancerCholangiocarcinomaAppendiceal Adenocarcinoma+6 more
Apollo Therapeutics Ltd 100
Large-scale testing (Phase 3)Active Not RecruitingNCT05374512
What this trial is testing

Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

Who this might be right for
Breast Cancer
AstraZeneca 644
Testing effectiveness (Phase 2)WithdrawnNCT05539365
What this trial is testing

Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma+1 more
Roswell Park Cancer Institute
Next Page